BRIA
BriaPro Therapeutics reports $299,950 in cash for interim period.
BriaPro Therapeutics Corp. filed unaudited interim financial statements for the period ended April 30, 2026, showing a substantial increase in total assets. The filing highlights a significant improvement in liquidity to approximately $300,000 in cash and cash equivalents, contrasting with the minim…
BRIA
BriaCell issues placement agent warrants exercisable from June 2026
BriaCell Therapeutics filed a warrant agreement allowing placement agents to purchase common shares starting June 2, 2026, expiring five years later per FINRA rules. The warrant issuance is typical financing activity for biotech companies seeking to incentivize capital raising intermediaries.
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.